top of page

Biotech Funding

Bar chart illustrating major longevity fund closes from July to November 2025, showing funding amounts for Frazier Life Sciences, Sofinnova Partners, Omega Funds, Sanofi Ventures, Catalio Capital, Atlas Venture, Ascenta Capital, Brandon Capital Fund VI, and Hatteras Venture Partners.

Bar chart illustrating major longevity fund closes from July to November 2025, showing funding amounts for Frazier Life Sciences, Sofinnova Partners, Omega Funds, Sanofi Ventures, Catalio Capital, Atlas Venture, Ascenta Capital, Brandon Capital Fund VI, and Hatteras Venture Partners.

Fall 2025 Capital Deployment: A Defining Moment for Longevity Investment

More than $5B in longevity and biotech capital was raised globally between July and November 2025. From reprogramming therapeutics to preventive clinics, the sector is entering a pivotal consolidation phase. Here’s what the new funding wave means for longevity’s future.

Longevity Investors

Nov 213 min read

bottom of page